Effetti della supplementazione di urolitina A sul metabolismo del glucosio negli adulti sani di età superiore a 55 anni: uno studio clinico randomizzato controllato in triplo mascheramento
Gli effetti della supplementazione di urolitina A sul metabolismo del glucosio negli adulti sani >= 55 anni. Uno studio clinico controllato randomizzato in triplo mascheramento
Background:
As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.
Objective:
To learn if UA improves levels of insulin and other hormones that help control blood glucose.
Eligibility:
People aged 55 years and older with a body mass index of 27 or higher.
Design:
Participants will have 6 clinic visits over 8 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function.
UA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking.
Participants will have tests during the study including:
Oral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours.
Continuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study.
Exercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces.
Imaging scans of the thigh; scans of the brain are optional....
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Study Description:
We hypothesize that supplementation with the nutritional supplement urolithin A (UA) in healthy adults >= 55 years old will; (i) increase insulin secretion by boosting beta cell metabolism of glucose, resulting in increased ATP generation as pyruvate enters the TCA cycle after glycolysis, thereby enhancing early, acute insulin secretion and glucose uptake in skeletal muscle -both of which will lower circulating levels of blood glucose, (ii) boost production and secretion of incretin hormones because their secretion is also dependent on cellular depolarization, (iii) boost mitochondrial function in brain and muscle tissues. (iv) alter gut microbiome. These effects will be examined over an 8-week period. The study will include a Screening Visit and 5 additional study visits.
Objectives:
Primary Objective:
To determine if UA supplementation will increase the rate at which beta cells respond to glucose.
Secondary Objectives:
Investigate if UA alters incretin secretion in response to oral glucose (incretins are secreted only in response to nutrients) and uncover if UA increases brain and skeletal muscle metabolism.
Endpoints:
Primary Endpoint:
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Secondary Endpoints:
- To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
- To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
- To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
- To determine if UA supplementation will alter gut microbiome composition.
- To determine if Uroltihin A supplementation alters the percentage of immune cell types.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Josephine M Egan, M.D.
- Numero di telefono: (410) 558-8414
- Email: eganj@mail.nih.gov
Backup dei contatti dello studio
- Nome: Denise L Melvin, R.N.
- Numero di telefono: (410) 350-3924
- Email: melvinde@mail.nih.gov
Luoghi di studio
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21224
- Reclutamento
- National Institute of Aging, Clinical Research Unit
-
Contatto:
- Josephine Egan, M.D.
- Numero di telefono: 410-558-8414
- Email: eganj@mail.nih.gov
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availably for the duration of the study.
- Male or female, age >= 55 years.
- Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit).
- BMI >= 27.
- Ability to take oral medication and be willing to adhere to the daily regimen.
- Ability to perform walking and treadmill tests without physical limitations.
- In good general health, as evidenced by medical history/physical exam/laboratory results.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- History of diabetes requiring treatment with any glucose lowering drug(s).
- Fasting glucose >= 126 on screening visit.
- Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.
- Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.
- History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.
- Uncontrolled thyroid disease.
- Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.
- History of chronic kidney disease or GFR <60 mL/min/1.73 m^2.
- Anemia (defined as hemoglobin level <12 g/dl for men or < 11 g/dl for women).
- Poor venous access.
- Uncontrolled hypertension as judged by the Investigator.
- History of significant GI disease, e.g., IBS, Crohn s disease.
- Active cancer or has had treatment for cancer in the last 1 year.
- Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.
- Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.
- History of, or laboratory evidence of HIV virus infection at Screening Visit.
- History of, or laboratory evidence of Hepatitis B or C at Screening Visit.
- Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).
- Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form.
- Weight >= 300 lbs (MRI scanner weight limit).
- Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.
- Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.
- Current smoker or tobacco use in the past year.
- History of substance abuse, including marijuana use in the past year.
- On average, consumes more than 1 alcoholic drink per day.
- Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
50% of participants |
The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A. |
|
Comparatore attivo: Urolithin A
50% of participants |
Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Lasso di tempo: 8 weeks
|
Study visits 1 - 5 |
8 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
Lasso di tempo: 8 weeks
|
Study visits 1 - 5 |
8 weeks
|
|
To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
Lasso di tempo: 8 weeks
|
Study visits 1 & 5 |
8 weeks
|
|
To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
Lasso di tempo: 8 weeks
|
Study visits 1 & 5 |
8 weeks
|
|
To determine if UA supplementation will alter gut microbiome composition.
Lasso di tempo: 8 weeks
|
Study visits 1, 3 & 5 |
8 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Josephine M Egan, M.D., National Institute on Aging (NIA)
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 10001930
- 001930-AG
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .